Equities analysts expect Immune Design Corp (NASDAQ:IMDZ) to report sales of $800,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Immune Design’s earnings. The highest sales estimate is $1.03 million and the lowest is $570,000.00. Immune Design posted sales of $490,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 63.3%. The business is expected to issue its next quarterly earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Immune Design will report full-year sales of $3.20 million for the current fiscal year, with estimates ranging from $1.70 million to $6.00 million. For the next year, analysts expect that the firm will post sales of $6.88 million, with estimates ranging from $2.20 million to $16.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Immune Design.

Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. Immune Design had a negative net margin of 2,409.84% and a negative return on equity of 43.44%. The firm had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.75 million.

Several analysts recently weighed in on the company. Zacks Investment Research upgraded Immune Design from a “sell” rating to a “hold” rating in a report on Wednesday, October 3rd. Leerink Swann downgraded shares of Immune Design from an “outperform” rating to a “market perform” rating in a report on Friday, October 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 target price on shares of Immune Design in a report on Friday, October 12th. HC Wainwright set a $8.00 target price on shares of Immune Design and gave the stock a “buy” rating in a report on Friday, October 12th. Finally, ValuEngine upgraded shares of Immune Design from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $7.13.

In related news, major shareholder Bvf Partners L. P/Il sold 902,000 shares of Immune Design stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $1.83, for a total transaction of $1,650,660.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 927,466 shares of company stock worth $1,690,895. 18.10% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc lifted its stake in Immune Design by 0.7% during the third quarter. Vanguard Group Inc now owns 1,615,442 shares of the biotechnology company’s stock worth $5,574,000 after purchasing an additional 11,006 shares during the period. Marshall Wace LLP acquired a new stake in Immune Design during the 3rd quarter worth $36,000. Nexthera Capital LP acquired a new stake in Immune Design during the 3rd quarter worth $146,000. Renaissance Technologies LLC acquired a new stake in Immune Design during the 3rd quarter worth $508,000. Finally, Bridgeway Capital Management Inc. grew its holdings in Immune Design by 172.1% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 221,192 shares of the biotechnology company’s stock worth $763,000 after acquiring an additional 139,900 shares during the period. Hedge funds and other institutional investors own 46.27% of the company’s stock.

Shares of NASDAQ:IMDZ traded down $0.14 on Thursday, hitting $1.51. 119,255 shares of the company’s stock were exchanged, compared to its average volume of 292,575. Immune Design has a 12 month low of $1.10 and a 12 month high of $5.05. The company has a market cap of $72.25 million, a price-to-earnings ratio of -0.86 and a beta of 2.43.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

See Also: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.